Day: March 4, 2026

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Written by Customer Service on March 4, 2026. Posted in Public Companies.

– Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes – – Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain – KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes. Through its acquisition of Evoke Neuroscience, Inc. and the...

Advanced Flower Capital Inc. Announces Financial Results for the Fourth Quarter and Full Year 2025

Written by Customer Service on March 4, 2026. Posted in Dividend Reports And Estimates.

Fourth quarter 2025 GAAP net income of $0.9 million or $0.04 per basic weighted average common share and Distributable Earnings(1) of $(2.8) million or $(0.12) per basic weighted average common share Full year 2025 GAAP net loss of $(20.7) million or $(0.95) per basic weighted average common share and Distributable Earnings of $8.7 million or $0.39 per basic weighted average common share WEST PALM BEACH, Fla., March 04, 2026 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (Nasdaq: AFCG) (“AFC,” or the “Company”) today announced its results for the fourth quarter and year ended December 31, 2025. AFC reported generally accepted accounting principles (“GAAP”) net income of $0.9 million, or $0.04 per basic weighted average common share, and Distributable Earnings of $(2.8) million, or $(0.12) per basic weighted average common share,...

Xanadu Hosts Analyst Day Highlighting Strategic Milestones and Path to Public Listing

Written by Customer Service on March 4, 2026. Posted in Mergers And Acquisitions.

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Inc. (“Xanadu”), a leading photonic quantum computing company, today is hosting its 2026 Analyst Day at the Nasdaq MarketSite in New York, in advance of the anticipated closing of its previously announced business combination with Crane Harbor Acquisition Corp. (“Crane Harbor”) (Nasdaq: CHAC). “We are encouraged by the level of interest from the financial community as we host our Analyst Day today,” said Christian Weedbrook, Founder and Chief Executive Officer of Xanadu. “As we move closer to becoming a publicly listed company, we recognize that our photonic approach to quantum computing represents a new and differentiated opportunity in the public markets. With scalable networking demonstrated and peer reviewed, and a path toward commercialization, we believe...

George Weston Limited Reports Adjusted Diluted Net Earnings Per Common Share Growth of 15.2% in the Fourth Quarter

Written by Customer Service on March 4, 2026. Posted in Earnings Releases And Operating Results.

TORONTO, March 04, 2026 (GLOBE NEWSWIRE) — George Weston Limited (TSX: WN) (“GWL” or the “Company”) today announced its consolidated unaudited results for the 13 weeks ended December 31, 2025(2). GWL’s 2025 Annual Report includes the Company’s audited annual consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) for the fiscal year ended December 31, 2025. The 2025 Annual Report has been filed on SEDAR+ and is available at www.sedarplus.ca and in the Investor Centre section of the Company’s website at www.weston.ca. As a result of the Company’s reporting calendar, the fourth quarter and full year 2025 include an extra week of operations (“the 13th week” or “the 53rd week”)(1) compared to the fourth quarter and full year 2024. “2025 marked another strong year for George Weston as Loblaw gained...

Dycom Industries, Inc. Reports Fiscal 2026 Fourth Quarter and Annual Results and Provides Fiscal 2027 Outlook

Written by Customer Service on March 4, 2026. Posted in Earnings Releases And Operating Results.

Exceeds Top End of Fiscal 2026 Revenue Outlook and Reports Record Q4 ResultsOperational Excellence Drives Record Free Cash FlowCompletes Strategic Acquisition of Power Solutions Accelerating Entry into High-Growth Data Center MarketFiscal 2027 Outlook Reflects Continued Organic Contract Revenue Growth and Adjusted EBITDA Margin Expansion Fourth Quarter Highlights(All metrics compared to the fourth quarter of fiscal 2025)Contract revenues of $1.458 billion(*) increased 34.4%, or 16.6% organically Net income of $16.3 million, or $0.55 per common share diluted Adjusted Net Income of $60.5 million(*), or $2.03(*) per common share diluted Adjusted EBITDA of $162.4 million(*), or 11.1% of contract revenues Operating cash flow of $419.0 million(*) Total backlog of $9.542 billion(*) Completed acquisition of Power Solutions, LLC on December 23,...

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

Written by Customer Service on March 4, 2026. Posted in Earnings Releases And Operating Results.

– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments. “Following a year of exceptional execution across our pivotal DURAVYU...

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on March 4, 2026. Posted in Earnings Releases And Operating Results.

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three...

Parex Resources Announces 2025 Full-Year Results, Reserves Per Share Growth, and Declaration of Q1 2026 Dividend

Written by Customer Service on March 4, 2026. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, March 04, 2026 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three- and twelve-month periods ended December 31, 2025, as well as the results of its independent reserves assessment as at December 31, 2025. Additionally, the Company declares its Q1 2026 regular dividend of C$0.385 per share and provides an operational update. All amounts herein are in United States dollars (“USD”) unless otherwise stated. Key HighlightsGenerated annual funds flow provided by operations (“FFO”)(1) of $455 million and free funds flow(2) of $145 million in 2025. Increased both PDP and 1P reserves per share by 4% and 2P reserves per share by 8%, compared to 2024(3). Strong PDP, 1P, and 2P reserves replacement at 106%, 106%,...

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Written by Customer Service on March 4, 2026. Posted in Public Companies.

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) — Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio (“Fermbox”), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free). This represents the first commercialized product under the companies expanded collaboration announced in 2025 and marks another step in Dyadic’s accelerating transition from platform development to commercial product expansion and recurring revenue...

JZXN Announces Groundbreaking US$1 Billion Plan to Acquire 10,000 BTC from Strategic Investor, Strengthening Global Cryptocurrency Partnership

Written by Customer Service on March 4, 2026. Posted in Public Companies.

HANGZHOU, March 04, 2026 (GLOBE NEWSWIRE) — Jiuzi Holdings, Inc. (Nasdaq: JZXN) (the “Company” or “JZXN”) today announced a transformative strategic agreement with a prominent global digital asset investor. Under the proposed landmark plan, the strategic investor will transfer 10,000 Bitcoins (BTC) to JZXN in exchange for equity consideration valued at approximately US$1 billion, while the two parties establish a deep, long-term strategic partnership to strengthen collaboration across the global cryptocurrency ecosystem. This definitive strategic plan represents a major milestone in JZXN’s digital asset expansion roadmap. The acquisition of 10,000 BTC will significantly enhance the Company’s digital asset treasury reserves, reinforce balance sheet strength, and elevate JZXN’s position within the global cryptocurrency market. The...

Day: March 4, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals